The aim of the present study was to retrospectively analyse the variability of uptake of the radiolabelled PSMA‐ligand [18F]PSMA‐1007 in organs at risk, and secondary to investigate the relationship between the uptake in organs at risk and tumour burden, in patients who underwent PET‐CT for the management of prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.